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Multi-detector computed tomographyBackground: Coronary artery aneurysm (CAA) is occasionally detected on a small percentage of coronary angiog-
raphy ormulti-detector computed tomography (MDCT). CAA itself is considered benign entity despite the poten-
tial risks of rupture, thromboembolism, and compression of surrounding structures. However, the optimal
management including other vascular comorbidity has yet to be fully clariﬁed.
Objective:The aimof this studywas to evaluate cardiovascular events in the patientswith CAA in the observation-
al group.
Methods: Between January 2010 and August 2015, 48 CAAs were identiﬁed in 37 patients out of consecutive
10,010 patients (0.37%) by MDCT. Twenty-eight patients treated conservatively were included in this study.
Their major adverse cardiovascular events (MACE) were evaluated retrospectively: death, non-fatal myocardial
infarction (MI), revascularizations; coronary artery bypass grafting (CABG) and percutaneous coronary interven-
tion (PCI), and other vascular events.
Results: The average age was 62.0 ± 15.5 year sold, and median follow-up period was 49.6 months (IQR 23.6 to
78.1). Mean CAA diameter was 7.5 ± 2.8 mm. Twenty-two MACE occurred in 15 patients (53.6%): 1 sudden
death, 4 MI, 1 CABG for CAA, 3 PCI for CAA, 7 PCI for non-CAA lesions, and 6 other vascular treatments for
aorta and cerebral and peripheral artery. Follow-up MDCT was performed for 22 CAAs in 16 patients. In 9
CAAs of them, the maximal diameter increased signiﬁcantly (Δ diameter: 1.5 ± 1.1 mm).
Conclusions: Presence of CAA may be associated with adverse vascular events including non-coronary diseases.
This study could suggest the management for CAA should include the evaluation of not only CAA itself but also
other vascular diseases.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coronary artery aneurysm (CAA) is occasionally detected on a small
percentage of coronary angiography (CAG) ormulti-detector computed
tomography (MDCT). The prevalence of CAA is reported as 0.3–5.3% in
CAG and MDCT [1–4], and as 1.4% in autopsy [5]. The majority of pa-
tients have CAA that is due to atherosclerosis [1,4,6], and the prognosis
of CAA is considered directly related to the severity of the concomitant
obstructive coronary artery disease [3,7,8]. So, CAA itself is considered
as benign entity despite the potential risks of rupture, thromboembo-
lism, and compression of surrounding structures. However, CAA is
sometimes associated with other vascular diseases, such as cerebrovas-
cular disease, macro-vascular disease like abdominal aortic aneurysm
(AAA), and peripheral artery disease [1,5,8]. Otherwise, only a few1 Wanagaya, Matsudo, Chiba,
ura).
nd Ltd. This is an open access article unreports mention the risk of these comorbidities [9–11]. So, the optimal
management for CAA including other vascular comorbidity has yet to
be fully clariﬁed. The purpose of this studywas to evaluate cardiovascu-
lar events in the patients with CAA, not only about coronary artery but
also other vascular diseases.
2. Method
2.1. Patients
Between January 2010 and August 2015, 48 CAAs were identiﬁed in
37 patients out of consecutive 10,010 patients by MDCT (0.37%). All
of MDCT was performed aimed to close investigation for ischemic
heart disease and rule out of coronary artery disease before non-
cardiovascular surgical operation. CAA is deﬁned as localized coronary
artery dilatation 1.5 times the diameter of the adjacent coronary artery
segment [1]. The term “localized” means involving less than 50% of the
total length of the vessel. By this deﬁnition, the term “ectasia”, deﬁnedder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics.
Patient characteristics 28 patients
Age, y 62.0 ± 15.5
Men, n (%) 18 (64.3)
Median f/u period, m 49.6 (IQR 23.6 to 78.1)
Coronary Risk Factors
HT, n (%) 18 (64.3)
DL, n (%) 16 (57.1)
DM, n (%) 4 (14.1)
CKD, n (%) 4 (14.1)
Smoke, n (%) 16 (57.1)
Family History of CAD, n (%) 4 (14.1)
systolic BP, mmHg 130.0 ± 15.1
diastolic BP, mmHg 74.5 ± 9.5
HT=hypertension,DL=dyslipidemia,DM=diabetesmellitus, CKD=chronic kidney,
disease, CAD = coronary artery disease, BP = blood pressure.
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jacent coronary artery segment that involves 50% or more of the
length of the artery [12], was not included in this study. The patients
were retraced when their CAAs were ﬁrst detected (the data was de-
ﬁned as “onset”) and their long-term major adverse cardiovascular
events (MACE) were evaluated retrospectively. MACE was deﬁned
as death, non-fatal myocardial infarction (MI), revascularizations;
coronary artery bypass grafting (CABG) and percutaneous coronary
intervention (PCI), and intervention for other vascular events, such
as cerebrovascular disease, macro-vascular disease like AAA, and pe-
ripheral artery disease. Because 9 patients (11 CAAs) immediately
treated with invasive therapy after ﬁrst detection of CAAs were ex-
cluded, 28 patients (37 CAAs) treated conservatively at ﬁrst were in-
cluded in this study as an observational group. The study protocol
conformed to the ethical guidelines of the 1975 Declaration of
Helsinki and all patients gave written informed consent approved Re-
search Ethics Committee in our institution. The study ﬂow was shown
in Fig. 1.
2.2. Statistical Analysis
Continuous variables were expressed asmean and (±) standard de-
viation (SD) or as median accompanied by interquartile range (IQR), as
appropriate. All the statistical analysis was performed using SPSS 20.0
(SPSS, Inc., Chicago, IL, USA).
3. Results
3.1. Patient and aneurysm characteristics
The average age at onset was 62.0 ± 15.5 year-old, and median
follow-up period was 49.6 months (IQR 23.6 to 78.1). Men were
observed in 64.3%. Diabetes mellitus and chronic kidney disease were
less observed than other coronary risk factors. Other patient character-
istics ware shown in Table 1. Mean CAA diameter at onset was 7.5 ±
2.8 mm. About the distribution of CAA, the right coronary artery was
most frequently involved (48.6%), followed by the left descending cor-
onary artery (40.5%). Three-vessel involvement was not observed. On
the basis of morphologic appearance, saccular aneurysm, deﬁned as
the transverse diameter is greater than the longitudinal measurement
of the aneurysm [12], was observed in 24.3%. Fusiform aneurysm, de-
ﬁned as the longitudinal diameter is greater than the transverse mea-
surement of the aneurysm [12], was more frequently seen (75.7%).
Almost 60% of CAA occurred as a consequence of atherosclerosis,Fig. 1. Study ﬂow. Between January 2010 and August 2015, 48 CAAs were identiﬁed in 37
patients out of consecutive 10,010 patients (0.37%) byMDCT. Twenty-eight patients treated
conservatively at ﬁrst were included in this study. Pts = patients, MDCT =multi-detector
computed tomography, CAA= coronary artery aneurysm.followed by Kawasaki disease (14.3%). Iatrogenic CAA as a consequence
of complication of PCI and Bentall operation was observed in one and
one each. Other aneurysm characteristics were shown in Table 2. Aspi-
rin wasmost frequently administered to these patients (71.4%), follow-
ed by clopidogrel (42.9%). Anticoagulant agent was less administered
(14.3%) than antiplatelet agent, and novel oral anticoagulant (NOAC)
was not administered at all (Table 3).
3.2. Outcome
Clinical outcome was shown in Table 4. MACE occurred in 15 pa-
tients out of 28 patients (53.6%), and total 22 adverse events were
counted. One sudden death (3.6%), 4 MI (14.3%), including 3 CAA relat-
ed MI, 1 CABG for CAA with stenosis (3.6%), 3 PCI for CAA with stenosis
(10.7%), 7 PCI for non-CAA lesions (25.0%), 2 coil embolization for cere-
bral artery aneurysm (7.1%), 2 surgical operation for AAA (7.1%), 1 sur-
gical operation for annuloaortic ectasia (3.6%), and 1 percutaneous
transluminal angioplasty for arteriosclerosis obliterans (3.6%). At each
physician's discretion, follow-up MDCT was performed for 22 CAAs in
16 patients. In 9 CAAs of them, the maximal diameter increased signiﬁ-
cantly:Δ diameter 1.5± 1.1mm in themedian follow-up period of 66.5
months (IQR 61.3–77.2).
4. Discussion
According to this study, presence of CAA seemed highly associated
with major adverse cardiovascular events. In general, the prognosis ofTable 2
Aneurysm characteristics.
Aneurysm characteristics 28 Pts, 37 CAAs
Size at onset, mm 7.5 ± 2.8




Form, n (%) Saccular 9 (24.3)
Fusiform 28 (75.7)
Etiology, n (%) atherosclerosis 16 (57.1)
Kawasaki disease 4 (14.3)
polycystic kidney disease 1 (3.6)
ﬁstula 2 (7.1)
Marfan syndrome 1 (4.5)
post-Bentall operation 1 (4.5)
post-stent 1 (4.5)
unknown 2 (7.1)
Pts = patients, CAA = coronary artery aneurysm, LMT = left main trunk, LAD = left
anterior descending artery, LCx = left circumﬂex, RCA = right coronary artery,
Table 3
Medication.
Medication, n (%) 28 patients
Antiplatelet Aspirin 20 (71.4)
Clopidogrel 12 (42.9)
Cilostazol 1 (3.6)
Anticoagulant Warfarin 4 (14.3)
NOAC 0 (0.0)
NOAC = novel oral anticoagulant.
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structive coronary artery disease [3,7,8]. However, almost one third of
MACE in this study was concerning non-coronary vascular disease. In-
deed, several literatures describe that CAA is sometimes associated
with other vascular diseases, particularly aortic and iliofemoral aneu-
rysms [1,5,8,13,14]. Otherwise, only a few reports mention the risk of
these comorbidities [9–11]. That may due to insufﬁcient estimation of
other vascular diseases and asymptomatic entities of aortic, carotid
and cerebral artery diseases. To the best of our knowledge, this study
put ﬁrst clearly emphasis on the risk of multi-vascular diseases of the
patients with CAA, except for case report [15].
This study included various type of CAA. However, etiology, distribu-
tion, morphologic appearance and patient characteristics such as high
prevalence of hypertension and dyslipidemia, and low prevalence of
diabetes mellitus in this study were very similar to those described in
former studies [1,3,4,6,12,14,16]. So, the population in this study could
represent overview image of CAA in the real world.
MACE seemed more frequently in CAA due to atherosclerosis, 16
events in 16 patients, compared to 6 events in 12 non-atherosclerotic
patients, although lacking statistical power. Saccular aneurysm is con-
sideredmore prone to thrombosis and rapture [17]. It is also considered
aneurysm size is not associatedwithmortality [18] and rapture of aneu-
rysm is rare and unpredictable [3,19]. We found 9 saccular aneurysms
and 9 enlarging aneurysms. But we could not ﬁnd out whether these
features contained the risk of MACE or not because of insufﬁcient statis-
tical power. Further studies including multicenter registries are needed
in order to clarify what type of CAA has more risk of multi-vascular
diseases.
5. Study Limitations
This study had several limitations, such as single center, small size,
and retrospective study. Original selection bias as many of patients
who underwent MDCT were suspected coronary artery disease was in-
evitable. Follow-up periodwas not uneven for each patient in this study
design. There was excluded population, such as moderate and severe
chronic kidney disease and contra-indication of MDCT. The late stentTable 4
Clinical outcome.
MACE, n (%) 15/28 patients (53.6)
Sudden death 1 (3.6)
non-fatal MI 4 (14.3)
CABG for CAA 1 (3.6)
PCI for CAA 3 (10.7)
PCI for non-CAA lesions 7 (25.0)
Coil embolization for cerebral aneurysm 2 (7.1)
Surgical operation for AAA 2 (7.1)
Surgical operation for AAE 1 (3.6)
PTA for ASO 1 (3.6)
MACE was deﬁned as death, non-fatal myocardial infarction, revascularization, and other
vascular events. MACE occurred in 15 patients out of 28 patients (53.6%), and total 22
adverse events were counted.
MI = myocardial infarction, CABG = coronary artery bypass grafting, CAA = coronary
artery aneurysm, PCI = percutaneous coronary intervention, AAA = abdominal aortic
aneurysm, AAE = annuloaortic ectasia, PTA percutaneous transluminal angioplasty,
ASO = arteriosclerosis obliterans.malposition and aneurysmal formation is often seen in drug-eluting
stent era [20–21]. However, there was only one post-stent aneurysm
observed despite a study in high volume PCI center. It was mainly be-
cause these CAAswere usually closely followedwith intravascular ultra-
sound imaging or optical coherence tomography in our institution.
6. Conclusions
Cardiovascular events in the patients with CAA in the observational
group cannot be ignored. This study suggested the management of
these patients should include not only evaluation of CAA itself but also
other vascular diseases.
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